Hainan Longevity
Guides & research · UC-MSC therapy for liver cirrhosis

Stem cells for liver cirrhosis, explained

Umbilical-cord mesenchymal stem cells, infused over three weeks in a licensed hospital — a clinical-stage disease treatment for compensated cirrhosis. What it is, who qualifies, and what it cannot do.

What a mesenchymal stem cell is, and why the liver

Mesenchymal stem cells (MSCs) are stromal cells that live in connective tissue and, in the umbilical cord, in the jelly that cushions the cord’s vessels. They are not embryonic cells and they do not become liver on demand. What they do, reliably and measurably in the laboratory, is signal: they secrete a broad set of growth factors and cytokines, they home toward injured tissue, and they dampen the immune reactions that keep chronic injury going. Umbilical-cord MSCs (UC-MSCs) are isolated from donated cord tissue after screened, consented birth, expanded in a licensed GMP facility, characterised, and released as a standardised product. Because MSCs carry very little of the surface signature that provokes rejection, they can be given without tissue matching — which is why a cord-derived cell can be infused into an unrelated adult.

Cirrhosis is the end state of chronic liver injury: hepatocytes die, hepatic stellate cells switch on and lay down collagen, the scar contracts, blood is forced around rather than through the organ, and synthetic function falls. The treating hospital’s filing describes three ways the infused cells are expected to act on that process. First, anti-fibrotic: MSC-secreted factors inhibit the activation and proliferation of hepatic stellate cells and push them toward apoptosis, while shifting the balance between the enzymes that degrade extracellular matrix (MMPs) and their inhibitors (TIMPs) toward breakdown of the fibrous scar. Second, immunomodulatory: the cells restrain T- and B-lymphocyte proliferation, raise suppressive cytokines and lower inflammatory ones, reducing the ongoing inflammatory damage to surviving hepatocytes. Third, regenerative signalling: the cells home to injured liver and release hepatocyte growth factor, insulin-like growth factor and interleukin-10, which promote hepatocyte proliferation; a fraction may take on hepatocyte-like characteristics or fuse with resident cells. The honest summary in the hospital’s own words is that MSCs may act on several stages of the disease at once — inflammation, fibrosis, regeneration — and that this is the basis on which the program is licensed as clinical-stage treatment. How cell products are released, and what the zone requires →

What it is licensed for here

Inside the Boao Lecheng pilot zone, UC-MSC infusion for cirrhosis is delivered by a tertiary hospital as a disease-treatment program under the zone’s clinical-stage licensing, and the filed criteria are specific. The indication is cirrhosis — not fatty liver, not “liver support”, not the hangover of a long career — established by a transient-elastography stiffness reading together with imaging and laboratory evidence of impaired synthetic function or portal hypertension, or by biopsy, according to China’s 2019 cirrhosis guideline. The patient must be between 18 and 75, in Child-Pugh class A or B, and able to understand and follow the protocol. Mainland regulation now confines cell therapy to disease indications, and the zone’s hospitals hold their licences on that basis; the retreat’s wellness side is built on the six-axis system, not on cells.

The class limit is the important one. Child-Pugh scores liver disease from bilirubin, albumin, clotting time, ascites and encephalopathy. Class A is compensated disease; class B is moderate; class C is advanced, decompensated cirrhosis. This program is for A and B. A decompensated patient with the complications listed below is not a candidate here, whatever their willingness to travel — and a separate, differently sourced MSC program in the zone addresses decompensated disease under its own criteria, which your care manager can describe if that is your situation.

How a course runs

Before you travel. Your hepatology records — the cause of the cirrhosis and its treatment, most recent elastography or imaging, liver panel, clotting, platelet count, any endoscopy findings and any history of ascites, bleeding or encephalopathy — go to the treating hospital’s panel over the secure channel your care manager opens. Candidacy is provisional until the on-island assessment confirms it.
Baseline assessment. The hospital’s pre-treatment panel is broad by design: full liver function and blood ammonia, a five-part coagulation screen including antithrombin activity, alpha-fetoprotein, hepatitis B serology, transient elastography, a low-dose chest CT and a contrast-enhanced MRI of the upper abdomen, alongside the general medicine, cardiac and body-composition baseline the retreat already takes. The four days, step by step →
Infusion. A course is three intravenous infusions, one a week for three consecutive weeks, each at a fixed cell dose of 1.5 × 108 cells. Each is a hospital admission with pre-infusion checks, a slow drip, and observation afterwards. The product is released against its batch specification before every infusion; a batch that misses on any release criterion is destroyed, not infused.
Mid-course and close. A shorter panel — liver function and the same coagulation screen — is repeated between infusions, and a post-course panel closes the treatment so the effect is measured against your own baseline rather than assumed.
Follow-up. Elastography and liver function are folded into your twelve-month follow-up calendar, and the course is reported into China’s national real-world data program as a condition of the licence.

The whole course therefore fits inside three weeks on the island, which is why cirrhosis is one of the few cell programs a guest can complete in a single stay. Hainan’s 30-day visa-free entry covers it with a week to spare; guests from East Asia sometimes prefer three short visits instead. The hospital’s evaluation package includes a short wellness stay around the assessment days.

Who is declined

The treating hospital’s panel applies fifteen filed exclusions before anything else is discussed, and some guests are declined. In plain language: any severe complication before treatment — hepatic encephalopathy, major gastrointestinal or variceal bleeding, refractory ascites, hepatorenal syndrome, liver failure; spontaneous bacterial peritonitis or any other serious infection; biliary obstruction, or cavernous transformation of the portal vein; significant renal impairment (creatinine at twice the upper limit or more), severe low sodium, or a low white-cell or neutrophil count; a history of splenectomy or devascularisation surgery; any malignancy within five years, with narrow exceptions for fully treated non-recurrent skin, superficial bladder and in-situ cancers; a major organ transplant, or severe heart, lung, kidney, blood or endocrine disease; drug dependence, methadone therapy or psychiatric illness; immunodeficiency including HIV; any history of deep-vein thrombosis or pulmonary embolism; pregnancy, breastfeeding or plans to conceive; an allergic constitution or known severe allergy to the product or its excipients; prior intolerance of cell therapy; and a liver transplant planned within three months. The panel keeps a final line for “any other condition that makes this treatment unsuitable”, and uses it.

The transplant exclusion is worth reading twice. If you are within three months of a transplant, the answer here is no — not because the cells would interfere, but because the transplant is the better treatment and nothing should delay it.

After each infusion

The hospital hands every patient the same aftercare sheet, and it is unglamorous. Rest, with gentle activity; keep warm. No hot springs, baths or steam rooms for a week after an infusion — a real constraint on an island whose retreat includes them, so your care manager schedules the hydrotherapy days around the infusion days. No X-ray or CT exposure for a month, which is why the imaging is done before the course, not after it. A light diet with more good-quality protein and seasonal fruit; no smoking, alcohol kept to a minimum, no strong tea or coffee. Regular sleep, 1.5 to 2 litres of water a day. Feeling restless and unable to sleep, or the opposite — tired and drowsy — in the days after an infusion is described as a normal adaptive reaction. A fever in the night is managed with a single dose of ibuprofen, taken with food, and reported to the care team in the morning.

What it cannot do

UC-MSC infusion does not cure cirrhosis, and it does not reverse the cause. If the cause is hepatitis B, antiviral therapy continues; if it is alcohol, cessation continues; if it is metabolic, the metabolic work continues. It does not replace endoscopic surveillance for varices, screening for hepatocellular carcinoma, or an assessment for transplant where one is indicated — and, as the exclusions make clear, it is not offered to anyone for whom a transplant is imminent. It is an adjunct: an attempt to slow or partly undo fibrosis and quiet inflammation alongside the plan your hepatologist has already set. It is clinical-stage medicine, lawful inside the zone precisely because outcomes are still being gathered, and no hospital in the zone may promise an outcome. Nor will we.

It is also not a longevity treatment. The same cell type is marketed elsewhere for “anti-ageing” and general rejuvenation; on the mainland that use is not licensed, and this program will not be offered to a healthy liver on that basis.

Why the zone, for this

Three things are true only here on the mainland. The therapy is licensed — cirrhosis is one of the disease areas named across the zone’s five approval batches of cell and gene technologies — and delivered in a tertiary hospital rather than a clinic. The cell product is released on-site against a filed specification. And outcome reporting is mandatory: every course enters a national real-world data program, the closest thing to a clinical-trial framework a patient can enter outside of one. Why Boao Lecheng →

If you have compensated cirrhosis — Child-Pugh A or B — and your hepatologist is open to an adjunct, write to us with the cause, your most recent elastography or imaging, and your last liver panel. A care manager will tell you honestly, within one working day, whether the panel is likely to consider you, before you plan three weeks around it.

Write to us →Tell us where you’re starting from — a care manager replies within one working day.